These findings provide a rationale for targeting PI3K/Akt/mTOR survival pathway for the treatment of patients with advanced bladder cancer, especially after failure of first-line chemotherapy such as cisplatin-based regimens. Here, MTOR is linked to urinary bladder carcinoma.